Maze Therapeutics, Inc. MAZE
We take great care to ensure that the data presented and summarized in this overview for Maze Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in MAZE
Top Purchases
Top Sells
About MAZE
Insider Transactions at MAZE
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 07
2026
|
Harold Bernstein President, R&D & CMO |
SELL
Open market or private sale
|
Direct |
25,156
-100.0%
|
$1,006,240
$40.2 P/Share
|
|
Jan 07
2026
|
Harold Bernstein President, R&D & CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,156
+50.0%
|
$251,560
$10.42 P/Share
|
|
Jan 07
2026
|
Catherine A. Sohn |
SELL
Open market or private sale
|
Direct |
26,920
-100.0%
|
$1,049,880
$39.11 P/Share
|
|
Jan 07
2026
|
Catherine A. Sohn |
BUY
Exercise of conversion of derivative security
|
Direct |
26,920
+23.92%
|
$269,200
$10.42 P/Share
|
|
Jan 06
2026
|
Catherine A. Sohn |
SELL
Open market or private sale
|
Direct |
2,493
-100.0%
|
$94,734
$38.62 P/Share
|
|
Jan 06
2026
|
Catherine A. Sohn |
BUY
Exercise of conversion of derivative security
|
Direct |
2,493
+50.0%
|
$24,930
$10.42 P/Share
|
|
Jan 05
2026
|
Harold Bernstein President, R&D & CMO |
SELL
Open market or private sale
|
Direct |
412
-100.0%
|
$16,480
$40.0 P/Share
|
|
Jan 05
2026
|
Harold Bernstein President, R&D & CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
412
+50.0%
|
$4,120
$10.42 P/Share
|
|
Jan 02
2026
|
Amy Bachrodt SVP, Finance |
SELL
Open market or private sale
|
Direct |
5,000
-15.03%
|
$195,000
$39.14 P/Share
|
|
Jan 02
2026
|
Amy Bachrodt SVP, Finance |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+11.3%
|
$50,000
$10.42 P/Share
|
|
Jan 02
2026
|
Harold Bernstein President, R&D & CMO |
SELL
Open market or private sale
|
Direct |
4,432
-100.0%
|
$177,280
$40.43 P/Share
|
|
Jan 02
2026
|
Harold Bernstein President, R&D & CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,432
+50.0%
|
$44,320
$10.42 P/Share
|
|
Dec 30
2025
|
Amy Bachrodt SVP, Finance |
SELL
Open market or private sale
|
Direct |
5,000
-27.83%
|
$200,000
$40.08 P/Share
|
|
Dec 30
2025
|
Amy Bachrodt SVP, Finance |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+13.08%
|
$50,000
$10.42 P/Share
|
|
Dec 30
2025
|
Atul Dandekar CSBO |
SELL
Open market or private sale
|
Direct |
100
-0.94%
|
$4,000
$40.36 P/Share
|
|
Dec 30
2025
|
Atul Dandekar CSBO |
BUY
Exercise of conversion of derivative security
|
Direct |
100
+0.93%
|
$1,000
$10.42 P/Share
|
|
Dec 29
2025
|
Amy Bachrodt SVP, Finance |
SELL
Open market or private sale
|
Direct |
10,000
-22.68%
|
$400,000
$40.85 P/Share
|
|
Dec 29
2025
|
Amy Bachrodt SVP, Finance |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+15.51%
|
$100,000
$10.42 P/Share
|
|
Dec 29
2025
|
Harold Bernstein President, R&D & CMO |
SELL
Open market or private sale
|
Direct |
45,000
-80.89%
|
$1,800,000
$40.64 P/Share
|
|
Dec 29
2025
|
Harold Bernstein President, R&D & CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
45,000
+50.0%
|
$450,000
$10.42 P/Share
|
Last 12 Months Summary
Buy / Acquisition
7.26M
Shares
From
8
Insiders
| Exercise of conversion of derivative security | 197K shares |
|---|---|
| Conversion of derivative security | 7.06M shares |
| Other acquisition or disposition | 1.49K shares |
Sell / Disposition
1.85M
Shares
From
7
Insiders
| Open market or private sale | 218K shares |
|---|---|
| Bona fide gift | 28.4K shares |
| Other acquisition or disposition | 1.6M shares |